Targets › OPRT
1 program from 1 company in 4 trials: 3 Phase 2, 1 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: the race on OPRT, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | S-1 Fluorouracil prodrug; inhibits thymidylate synthase and orotate phosphoribosyltransferase | TYMS, OPRT | Phase 2 | Biliary Tract Cancer; Pancreatic Adenocarcinoma; Intrahepatic Cholangiocarcinoma (Icc); Neuroendocrine Tumors | Dec 2026 |
Biliary Tract Cancer (1) Pancreatic Adenocarcinoma (1) Intrahepatic Cholangiocarcinoma (Icc) (1) Neuroendocrine Tumors (1)
–
Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.